Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy

Investors are pumping more money into one of the microbiome field's longest-standing biotechs to push it toward a Phase 3 readout in C. difficile next year. Cambridge, MA-based Vedanta Biosciences said Thursday its two main ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 6 August →